Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring

Pembrolizumab, a humanized monoclonal IgG4 antibody directed against programmed death-1, is an immune checkpoint inhibitor that has been introduced for the treatment of non-small-cell lung cancer. However, immune checkpoint inhibitors may cause severe immune-related adverse events. We herein present...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsume, Yumi, Isawa, Tsuyoshi, Toi, Yukihiro, Fukuda, Ryo, Kondo, Yasuteru, Sugawara, Shunichi, Ootomo, Tatsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262691/
https://www.ncbi.nlm.nih.gov/pubmed/29877257
http://dx.doi.org/10.2169/internalmedicine.0255-17
_version_ 1783375160602001408
author Katsume, Yumi
Isawa, Tsuyoshi
Toi, Yukihiro
Fukuda, Ryo
Kondo, Yasuteru
Sugawara, Shunichi
Ootomo, Tatsushi
author_facet Katsume, Yumi
Isawa, Tsuyoshi
Toi, Yukihiro
Fukuda, Ryo
Kondo, Yasuteru
Sugawara, Shunichi
Ootomo, Tatsushi
author_sort Katsume, Yumi
collection PubMed
description Pembrolizumab, a humanized monoclonal IgG4 antibody directed against programmed death-1, is an immune checkpoint inhibitor that has been introduced for the treatment of non-small-cell lung cancer. However, immune checkpoint inhibitors may cause severe immune-related adverse events. We herein present a case of lung cancer with complete atrioventricular block associated with acute myocarditis, which developed 16 days after the administration of pembrolizumab. The clinical course of this case suggested a strong need for close cardiac monitoring when pembrolizumab is administered on an outpatient basis.
format Online
Article
Text
id pubmed-6262691
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-62626912018-11-30 Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring Katsume, Yumi Isawa, Tsuyoshi Toi, Yukihiro Fukuda, Ryo Kondo, Yasuteru Sugawara, Shunichi Ootomo, Tatsushi Intern Med Case Report Pembrolizumab, a humanized monoclonal IgG4 antibody directed against programmed death-1, is an immune checkpoint inhibitor that has been introduced for the treatment of non-small-cell lung cancer. However, immune checkpoint inhibitors may cause severe immune-related adverse events. We herein present a case of lung cancer with complete atrioventricular block associated with acute myocarditis, which developed 16 days after the administration of pembrolizumab. The clinical course of this case suggested a strong need for close cardiac monitoring when pembrolizumab is administered on an outpatient basis. The Japanese Society of Internal Medicine 2018-06-06 2018-11-01 /pmc/articles/PMC6262691/ /pubmed/29877257 http://dx.doi.org/10.2169/internalmedicine.0255-17 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Katsume, Yumi
Isawa, Tsuyoshi
Toi, Yukihiro
Fukuda, Ryo
Kondo, Yasuteru
Sugawara, Shunichi
Ootomo, Tatsushi
Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring
title Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring
title_full Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring
title_fullStr Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring
title_full_unstemmed Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring
title_short Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring
title_sort complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262691/
https://www.ncbi.nlm.nih.gov/pubmed/29877257
http://dx.doi.org/10.2169/internalmedicine.0255-17
work_keys_str_mv AT katsumeyumi completeatrioventricularblockassociatedwithpembrolizumabinducedacutemyocarditistheneedforclosecardiacmonitoring
AT isawatsuyoshi completeatrioventricularblockassociatedwithpembrolizumabinducedacutemyocarditistheneedforclosecardiacmonitoring
AT toiyukihiro completeatrioventricularblockassociatedwithpembrolizumabinducedacutemyocarditistheneedforclosecardiacmonitoring
AT fukudaryo completeatrioventricularblockassociatedwithpembrolizumabinducedacutemyocarditistheneedforclosecardiacmonitoring
AT kondoyasuteru completeatrioventricularblockassociatedwithpembrolizumabinducedacutemyocarditistheneedforclosecardiacmonitoring
AT sugawarashunichi completeatrioventricularblockassociatedwithpembrolizumabinducedacutemyocarditistheneedforclosecardiacmonitoring
AT ootomotatsushi completeatrioventricularblockassociatedwithpembrolizumabinducedacutemyocarditistheneedforclosecardiacmonitoring

Ejemplares similares